- J&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsJ&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.BioPharma Dive · 13d ago↗ source
- STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and moreAn Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicinesSTAT · 13d ago↗ source
- What to know about the parasitic diarrhea outbreakFallout from the end of ACA subsidies, the FDA CBER acting director "on planet Earth," and more health news from Morning RoundsSTAT